The new guidelines provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings. These guidelines update the recommendations for managing hyperglycaemia in the WHO Package of Essential NCD I...nterventions (WHO PEN) for primary care in low-resources settings, reviewing several newer oral agents as second- and third-line treatment: dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter 2 inhibitors and thiazolidinediones. The guidelines also present recommendations on the selection of type of insulin (analogue versus human insulin) for adults with type 1 and type 2 diabetes.
more
In the post-colonial history of the Central African Republic, violence has often been the shortest way to presidential power. President Bozizé presented little deviation from this narrative after coming to power after a coup d’état in 2003. Whilst he faced armed opposition and a conflict-affecte...d northwest from the outset, it is not until the rise of the Séléka, that the CAR entered into an era of unprecedented violence.
more
Arabic Analysis on World about Agriculture, Climate Change and Environment, Drought, Flood and more; published on 09 Dec 2021 by FAO
Ce guide clinique et thérapeutique s’adresse aux professionnels de santé impliqués dans les soins curatifs au niveau des dispensaires et des hôpitaux. Nous avons essayé de répondre le plus simplement possible aux questions et problèmes auxquels est confronté le personnel de santé par des ...solutions pratiques, conciliant l’expérience acquise sur le terrain par Médecins Sans Frontières, les recommandations des organismes de référence tels que l’Organisation Mondiale de la Santé (OMS) et celles des ouvrages spécialisés en la matière.
more
Vaccinator's Manual. CONVIDECIA Vaccine
Preventing Physical Impairment in Childhood CBM Strategy Overview | Laminated flip charts | These are the main implementing tools in the prevention program, developed as A4 sized booklets which can be carried easily. They constitute the basic information a community rehabilitation worker needs to co...nvey to caregivers, primary health providers and other appropriate user groups. They are primarily visually presented, taking into consideration audiences with limited literacy, with three or four bullet points per page for the community workers to reinforce. The drawings can also be printed on A1 sized flip charts.
more
This booklet provides an overview of all findings from the Global Burden of Disease 2017 study. Published in The Lancet in November 2018, GBD 2017 provides for the first time an independent estimation of population, for each of 195 countries and territories and the globe, using a standardized, repli...cable approach, as well as a comprehensive update on fertility. Produced with the input of 3,676 collaborators from 146 countries and territories, GBD 2017 incorporates major data additions and improvements, and methodological refinements. GBD 2017 also includes estimates at the subnational level for selected locations.
more
Lettre du Saint-Pére Francois
Die Johanniter haben im Rahmen ihrer Aktivitäten im Bereich Flüchtlingshilfe und Integration allgemeine, niedrigschwellige Informationen zum Thema Corona-Impfung in verschiedenen Sprachen bereitgestellt. Diese dienen als Ergänzung zu den offiziellen Informationsmaterialien der Bundeszentrale für... gesundheitliche Aufklärung u.a. Die Informationsblätter wurden in Zusammenarbeit mit dem Ethno-medizinischen Zentrum e.V. Hannover übersetzt und werden bei Bedarf aktualisiert.
Die Informationsblätter sind in zahlreichen Sprachen verfügbar
more
Die Verordnung (EU) Nr. 604/2013 des Europäischen Parlaments und des Rates vom 26. Juni 2013 ist eine Verordnung der Europäischen Union, nach der der Mitgliedstaat bestimmt wird, der für die Durchführung eines Asylverfahrens zuständig ist. Die Verordnung tritt an die Stelle der Dublin-II-Verord...nung und wird auch Dublin-III-Verordnung genannt. Sie ist am 19. Juli 2013 in Kraft getreten und ist ihrem Art. 49 zufolge ab dem 1. Januar 2014 unmittelbar anzuwenden.
Andere Sprachversionen verfügbar siehe http://eur-lex.europa.eu/legal-content/DE/TXT/?qid=1445167987946&uri=CELEX:32013R0604
more
Peripheral artery disease (PAD) is the most underdiagnosed, underestimated and undertreated of the atherosclerotic vascular diseases despite its poor prognosis. There may be racial or contextual differences in the Asia-Pacific region as to epidemiology, availability of diagnostic and therapeutic mod...alities, and even patient treatment response. The Asian Pacific Society of Atherosclerosis and Vascular Diseases (APSAVD) thus coordinated the development of an Asia-Pacific Consensus Statement (APCS) on the Management of PAD.
more
In 2018, the Food and Agriculture Organization of the United Nations (FAO) in South Sudan must respond to the highest levels of food insecurity ever recorded in the country. To address this challenge, FAO revised its multiyear Emergency Livelihood Response Programme (ELRP) to enable rapid food produ...ction among the most vulnerable communities, protect their livelihoods and reduce dependency on humanitarian aid while building their resilience.
more
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more